Clinical Trials Browser

INDUSTRY × Expanded_access × Plasma cell × Clear all

Multiple Myeloma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Endometrial Neoplasms, Primary Myelofibrosis

NCT05346835 2026-02-13

Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

Available

Plasma cell

Multiple Myeloma

NCT03123029 2026-01-30

Expanded Access to Venetoclax

Available

LymphoidOther hematologic neoplasmPlasma cell

Amyloidosis, Leukemia, Plasma Cell, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

KEAP

Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

Expanded Access to Venetoclax

Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)

Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

Managed Access Programs for LDK378, Ceritinib

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients

Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma

Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)

Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma

MAGNETISMM17

Early Patient Access Treatment Use Protocol CA204-220

Expanded Access Treatment Protocol CA204-143

Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma

An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma

PEXIUS

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

Expanded Access for CC-4047

Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease

Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma

A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients

EAP

A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE